MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 13.02.2026
Amgen Operativer Cashflow 2011-2026 | AMGN
Operativer Cashflow Jährlich Amgen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.96 B | 11.5 B | 8.47 B | 9.72 B | 9.26 B | 10.5 B | 9.15 B | 11.3 B | 11.2 B | 10.4 B | 9.73 B | 8.95 B | 6.53 B | 5.88 B | 5.12 B |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 11.5 B | 5.12 B | 9.17 B |
Operativer Cashflow Vierteljährlich Amgen
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2.16 B | - | - | - | 2.1 B | - | 8.34 B | 4.98 B | 2.13 B | - | 6.64 B | 3.26 B | 1.84 B | - | 8.1 B | 4.83 B | 2.73 B | - | 8.16 B | 4.71 B | 2.38 B | - | 7.25 B | 4.59 B | 1.92 B | - | 7.66 B | 4.77 B | 1.48 B | - | 6.11 B | 3.37 B | 1.14 B | - | 4.46 B | 2.65 B | 1.05 B | - | 5.07 B | 3.35 B | 972 M | - | 3.54 B | 2.57 B | 1.03 B |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 8.34 B | 972 M | 3.92 B |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-147 M | - | - | $ 2.18 B | USA |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-12.9 M | - | -13.47 % | $ 169 M | France |
 |
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
456 M | $ 89.59 | - | $ 21.7 B | Germany |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 2.22 | - | $ 207 M |  Israel |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.58 | - | $ 185 M | USA |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
28.7 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
-110 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 29.93 | - | $ 1.99 B | USA |
 |
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-10.4 M | $ 0.79 | - | $ 36.1 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
10.5 M | $ 28.9 | - | $ 778 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-4.77 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-78.2 M | - | - | $ 384 M | Britain |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 16.69 | - | $ 216 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-483 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
11.2 M | $ 14.79 | - | $ 212 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.16 | - | $ 5.2 M | Israel |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 56.95 | - | $ 5.12 B |  Schweiz |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Galectin Therapeutics
GALT
|
-23.9 M | $ 2.38 | - | $ 152 M | USA |